Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -8.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | -8.11% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions impacting performance. They reiterated their focus on long-term goals.
Management highlighted ongoing challenges in the current market environment.
They emphasized their commitment to long-term strategies despite short-term setbacks.
Tyra Biosciences Inc reported a loss of $0.36 per share, which was slightly worse than expected. The stock fell by 3.32% following the announcement, reflecting investor concerns over the company's current challenges and lack of revenue data. The absence of guidance may leave investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Aug 1, 2022